These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10430149)

  • 21. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.
    Shamsi K; Yucel EK; Chamberlin P
    Invest Radiol; 2006 Nov; 41(11):822-30. PubMed ID: 17035873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transjugular intrahepatic portosystemic shunts: improved evaluation with echo-enhanced color Doppler sonography, power Doppler sonography, and spectral duplex sonography.
    Fürst G; Malms J; Heyer T; Saleh A; Cohnen M; Frieling T; Weule J; Hofer M
    AJR Am J Roentgenol; 1998 Apr; 170(4):1047-54. PubMed ID: 9530057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upper gastrointestinal tract and abdomen: water as an orally administered contrast agent for helical CT.
    Winter TC; Ager JD; Nghiem HV; Hill RS; Harrison SD; Freeny PC
    Radiology; 1996 Nov; 201(2):365-70. PubMed ID: 8888224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of barium as a gastrointestinal contrast agent in MR imaging: a comparison study in normal volunteers.
    Ros PR; Steinman RM; Torres GM; Burton SS; Panaccione JL; Rappaport DC; McGorray SP
    AJR Am J Roentgenol; 1991 Oct; 157(4):761-7. PubMed ID: 1892032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved US visualization of the pancreatic tail with simethicone, water, and patient rotation.
    Abu-Yousef MM; El-Zein Y
    Radiology; 2000 Dec; 217(3):780-5. PubMed ID: 11110943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
    Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
    J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary cost-effectiveness evaluation of an oral sonographic contrast agent using a decision modeling technique.
    LaFrance ND; Brooks K; Yin D; Parker JR; Bensel K; Macchi D; Lev-Toaff AS
    Acad Radiol; 1996 Aug; 3 Suppl 2():S426-31. PubMed ID: 8796621
    [No Abstract]   [Full Text] [Related]  

  • 28. Contrast-enhanced sonography of malignant pediatric abdominal and pelvic solid tumors: preliminary safety and feasibility data.
    McCarville MB; Kaste SC; Hoffer FA; Khan RB; Walton RC; Alpert BS; Furman WL; Li C; Xiong X
    Pediatr Radiol; 2012 Jul; 42(7):824-33. PubMed ID: 22249601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
    Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
    J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study of 2 dosage forms of liquid dimethicone for ultrasound premedication].
    Gladisch R; Elfner R; Ulrich H; Heene DL
    Ultraschall Med; 1990 Apr; 11(2):95-9. PubMed ID: 2192454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: results of phase I and phase II clinical trials.
    Tanimoto A; Kadoya M; Kawamura Y; Kuwatsuru R; Gokan T; Hirohashi S
    J Magn Reson Imaging; 2006 Apr; 23(4):499-508. PubMed ID: 16534755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of oral superparamagnetic contrast media in cholangiopancreatography with TSE single-shot magnetic resonance].
    Blandino A; Gaeta M; Mazziotti S; Settineri N; Pandolfo I
    Radiol Med; 1998; 96(1-2):87-91. PubMed ID: 9819624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): a phase II study.
    Kittner T; Rudolf J; Fages JF; Legmann P; Aschauer M; Repa I; Alvares MR; Savalegui I; Ittrich H; Geterud K; de Kevviler E; Ayuso J; Lockhart ME; Blum A; Iliasch H; Leisinger G; van Beek EJ; Reid AW; Brown JJ; Yu TC; Flamm SD; Düber C; Judmaier W; Reimer P; Stiskal M; Kramann B; Wolff S; Blankenstein C
    Eur J Radiol; 2007 Dec; 64(3):456-64. PubMed ID: 17412546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of simethicone as a patient preparation for abdominal sonography.
    Sommer G; Filly RA; Laing FC
    Radiology; 1977 Oct; 125(1):219-21. PubMed ID: 897173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized placebo-controlled trial of oral liquid simethicone prior to upper gastrointestinal endoscopy.
    Bertoni G; Gumina C; Conigliaro R; Ricci E; Staffetti J; Mortilla MG; Pacchione D
    Endoscopy; 1992 May; 24(4):268-70. PubMed ID: 1612040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients.
    Lowe LH; Kearns GL; Wible JH
    Curr Med Res Opin; 2006 Dec; 22(12):2515-24. PubMed ID: 17166334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease.
    Runge VM; Bradley WG; Brant-Zawadzki MN; Carvlin MJ; DeSimone DN; Dean BL; Dillon WP; Drayer BP; Flanders AE; Harms SE
    Radiology; 1991 Dec; 181(3):701-9. PubMed ID: 1947085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA].
    Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R
    Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.